A Phase 1 interventional study of V951A and Placebo in Healthy Volunteers, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This early study is testing an investigational vaccine called V951A. This study is looking for healthy volunteers. The main goals are to find out if the vaccine is safe, how well the human body handles different doses of it, and if it helps the body build immune defenses.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy younger adult participants (typically aged 18 to 49) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in a younger population.
Biological: V951A
Healthy older adult participants (typically aged 50 and older) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in an older population.
Biological: V951A
Healthy adult participants who will receive placebo injections containing no active vaccine. This group acts as a comparator to help researchers safely evaluate the effects of the active investigational vaccine.
Other: Placebo
Administered via intramuscular injection.
Administered via intramuscular injection.
Percentage of Participants With Solicited Injection-Site Adverse Events (AE)
An AE is defined as any untoward medical occurrence in a clinical database participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Solicited injection-site AEs are predetermined local reactions at the injection site (such as pain/tenderness, erythema/redness, and swelling) recorded on the participant's electronic diary card.
Time frame: Up to 7 days after each vaccination
Percentage of Participants with Solicited Systemic AE
An AE is defined as any untoward medical occurrence in a clinical database participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Solicited systemic AEs are predetermined body-wide reactions (such as headache, fever, fatigue, myalgia/muscle pain, and arthralgia/joint pain) recorded on the participant's electronic diary card.
Time frame: Up to 7 days after each vaccination
Percentage of Participants with Immediate Post-Vaccination AEs
This measures specific body-wide side effects monitored closely (typically fever, headache, fatigue, muscle pain, and joint pain).
Time frame: Up to 30 minutes after each immunization
Percentage of Participants with Unsolicited AEs
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. Unsolicited AEs are any unexpected, non-predetermined medical events reported by the participant that are not specifically listed on the daily diary card.
Time frame: Up to 28 days after each immunization
Percentage of Participants with Serious Adverse Events (SAEs)
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. A Serious Adverse Event (SAE) is any AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event that may jeopardize the participant.
Time frame: Up to approximately 18 months
Percentage of Participants with Medically Attended AEs (MAAEs)
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. A MAAE is defined as any AE that results in an unscheduled visit to a healthcare professional (such as a physician's office, clinic, or emergency room) for medical evaluation or treatment.
Time frame: Up to approximately 18 months
Percentage of Participants with Adverse Events of Special Interest (AESIs)
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. An AESI is a noteworthy medical event of clinical interest (such as a severe allergic reaction or specific neurological event) that has been designated for expedited tracking and continuous safety surveillance within this vaccine clinical program.
Time frame: Up to approximately 18 months
Geometric Mean Concentration (GMC) of V951A-Specific Antibodies
This measures the average amount of antibodies produced by the participants' immune systems in response to the V951A vaccine. The concentration is determined using a specialized laboratory assay.
Time frame: At designated time points and up to up to approximately 18 months
Percentage of Participants Achieving Seroconversion to V951A
Seroconversion is defined as a transition from a seronegative baseline (undetectable antibody levels prior to vaccination) to a seropositive post-vaccination status, or a pre-defined multi-fold increase (typically ≥ 4-fold) in antibody concentrations from baseline to post-vaccination as determined by a specialized laboratory assay.
Time frame: At designated time points and up to up to approximately 18 months
No study locations are listed for this record.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Start is estimated for Nov 2026; primary completion for Aug 2029, 32 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.